Observational studyJournal of cardiothoracic surgery2026
Impact of left ventricular ejection fraction on left ventricular thrombus resolution.
Observational study in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Exploratory Study of Effectiveness and Safety of Rivaroxaban in Patients With Left Ventricular Thrombus
Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoor left ventricular ejection fraction (LVEF) is associated with an increased risk of left ventricular (LV) thrombus formation. However, the effect of LVEF on thrombus resolution remains unclear.
methodsWe prospectively enrolled patients from 2020 to 2022 and retrospectively from 2010 to 2020 at the National Center for Cardiovascular Diseases, China. Patients with LV thrombus diagnosed within the last 3 months were included. The primary outcome was the resolution of LV thrombus at 12 weeks. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox regression, adjusting for potential covariates.
resultsA total of 380 patients on oral anticoagulation for ≥ 12 weeks were included, with a median age of 50.8 years (81.6% male). Dilated cardiomyopathy was the most common underlying condition (51.6%). Direct oral anticoagulants (DOACs) were prescribed to 53.7% of patients. The median baseline LVEF was 30%. In unadjusted analysis, thrombus resolution was higher in patients with LVEF ≤ 30% (78.5% vs. 63.9%, HR 0.61, 95%CI 0.48-0.78, P < 0.001). However, after adjustment for confounders, the difference was not significant (HR 0.79, 95%CI 0.61-1.03, P = 0.089). In multivariable analysis, DOAC use was associated with a higher likelihood of thrombus resolution compared to warfarin (HR 1.34, 95% CI 1.04-1.74, P = 0.024).
conclusionsBaseline LVEF was not a significant predictor of LV thrombus resolution after adjustment. DOACs were more effective than warfarin in promoting thrombus resolution, warranting further investigation.
trial registrationThis study was a combined cohort from two studies (ClinicalTrials.gov: NCT04970381, NCT05006677).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.